How to predict post TAVR quality of life in “real world” patients

Despite the benefit for most patients, a small number of patients still show poor outcomes after transcatheter aortic valve implantation (TAVR). This work was able to recalibrate a previously developed risk model to predict post TAVR quality of life and provide us with a potential tool to properly estimate the chances of good recovery, or to predict futility and altogether give up the procedure.

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVIThe prior prediction model was developed using data from randomized clinical studies of high-risk TAVR patients. However, this model did not work well with lower risk or unselected ‘real life’ patients. The aim of this study was to optimize this risk model to better predict poor outcomes after TAVR.

 

At one year, of 13351 patients undergoing TAVR in 252 centers in the US from 2011 to 2015, 38.9% had poor outcomes; 20.7% because of death, and 18.2% because of poor or worsening quality of life.


Read also: Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates.


This high rate has fortunately been receding: it has gone from 42% in 2012 to 37.8% in 2015 (p=0.076).

 

The original risk model based on randomized studies did not adjust well to this population of unselected patients.


Read also: Immediate Electrocardiography After TAVI, the Simplest Way to Predict Conduction Disorders.


The study recalibrated model coefficients and retested its capacity to predict poor outcomes, which improved its prediction capacity (both globally and in subgroups) reaching a C index of 0.65, and excellent calibration.

 

Conclusion

A great number of patients still show poor results after TAVR. This recalibrated prediction model at one year is far more accurate and might help us better identify TAVR candidates.

 

Original title: Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population.

Reference: Suzanne V. Arnold et al. Circ Cardiovasc Qual Outcomes. 2018;11:e004693.

 

2018-11-02-CIRCOUTCOMES


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....